Sam S. Chang MD, MBA, discusses intravesical mitomycin in low-grade intermediate-risk nonmuscle-invasive bladder cancer vs ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

A mucoadhesive nanoplatform improves bladder cancer imaging by selectively targeting tumors and enhancing visualization for more precise non-invasive diagnosis.

TYRA-300 is a potential first-in-class, investigational, oral, FGFR3-selective inhibitor designed to minimize the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic ...

EAU guidelines offer updated guidance on diagnosis, treatment, & follow-up of patients with metastatic & muscle-invasive ...

In a multi-institutional study published in Science Direct, researchers revealed that testing urine-based tumor DNA (utDNA) ...

BCG therapy—the gold standard treatment for non-muscle invasive bladder cancer (NMIBC), where the cancer has not penetrated ...

J&J acquired rights to TAR-200 when it bought privately-owned biotech Taris for an undisclosed sum in 2019, and has big sales expectations for the drug, even though it recently failed a second ...

People with urothelial carcinoma of the bladder are at risk for recurrence and progression following transurethral resection of a bladder tumour (TURBT). Mitomycin C (MMC) and Bacillus Calmette-Guérin ...